Compare ELTX & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | IPWR |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 65.4M |
| IPO Year | 2014 | 2013 |
| Metric | ELTX | IPWR |
|---|---|---|
| Price | $2.05 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $18.00 | $10.75 |
| AVG Volume (30 Days) | ★ 281.3K | 194.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | N/A | $2,603.56 |
| Revenue Next Year | N/A | $1,800.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.17 | $2.62 |
| 52 Week High | $16.00 | $9.30 |
| Indicator | ELTX | IPWR |
|---|---|---|
| Relative Strength Index (RSI) | 22.25 | 52.16 |
| Support Level | N/A | $4.77 |
| Resistance Level | $3.32 | $5.05 |
| Average True Range (ATR) | 0.13 | 0.29 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 4.33 | 55.13 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.